Our stories

Every day we're guided by our purpose to use the power of leading-edge science to save and improve lives around the world

How we’re collaborating to address antimicrobial resistance – and why we can’t do it alone

Shared commitments like the AMR Action Fund are vital to make progress against this public health threat

Diversity and inclusion strengthen everything we do

From fostering an inclusive and supportive culture to working with diverse suppliers, diversity and inclusion are integral to helping us better serve patients

Innovation

Macrocyclic peptides: the next wave of drug discovery

MSD scientists say the “Goldilocks” chemical modality could lead to new ways to impact disease

Innovation

Our Q3 2023 earnings report

MSD’s Q3 2023 results reflect sustained growth, particularly in oncology and vaccines. Our company announced Q3 worldwide sales of $16.0 billion, an increase of 7% from Q3 2022. “Our strong results this quarter reflect our talented team’s commitment to bringing forward important innovation and pursuing breakthroughs for all those who count on us,” said Rob Davis, chairman and […]

Every day we're guided by our purpose to use the power of leading-edge science to save and improve lives around the world

How we’re collaborating to address antimicrobial resistance – and why we can’t do it alone

Diversity and inclusion strengthen everything we do

Macrocyclic peptides: the next wave of drug discovery

Our Q3 2023 earnings report

You are leaving MSD.com